Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycystic Ovary Syndrome 2Insulin Resistance 2Inflammation 2Hyperandrogenism 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Anovulation 1

Interventions

Cyclophosphamide 69fludarabine phosphate 66Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 48Whole-Body Irradiation 47Tacrolimus 44Busulfan 43Cyclosporine 38Azacitidine 35Methotrexate 28Filgrastim 27Antilymphocyte Serum 27Cytarabine 26Decitabine 23Melphalan 22Radiotherapy 21fludarabine 20venetoclax 16Methylprednisolone 16Cyclosporins 13Cord Blood Stem Cell Transplantation 13Injections 12Granulocyte Colony-Stimulating Factor 12Flow Cytometry 12Specimen Handling 11Etoposide 11Biopsy 11Stem Cell Transplantation 10Sirolimus 10Clofarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Chronic × salicylsalicylic acid × Clear all
NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Rutgers, The State University of New Jersey

Phase 2 Completed
5 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡